Payment overview · 2025
General Payments
$225.47
10 reported records · 5 companies
Healthcare provider profile · identity verified
Tedi E. Payne
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · EL DORADO SPRINGS, MO · NPI 1083055800
Verified facts
What the public records show
CMS Open Payments records show Tedi E. Payne received $225.47 in general payments during 2025 across 10 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 32.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $73.56 | 32.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $60.22 | 26.7% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $38.54 | 17.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.32 | 16.6% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.83 | 7.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $186.93 | 9 |
| Education | $38.54 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $73.56 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $38.73 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $38.54 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 279 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 243 | 39 |
| Losartan Potassium | Losartan Potassium | 225 | 41 |
| Gabapentin | Gabapentin | 190 | 33 |
| Amlodipine Besylate | Amlodipine Besylate | 181 | 32 |
| Lisinopril | Lisinopril | 165 | 31 |
| Omeprazole | Omeprazole | 118 | 32 |
| Potassium Chloride | Potassium Chloride | 106 | 21 |
| Metformin Hcl | Metformin Hcl | 105 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 20 |
| Simvastatin | Simvastatin | 104 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 20 |
| Meloxicam | Meloxicam | 97 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 93 | 19 |
| Azithromycin | Azithromycin | 91 | 81 |
| Furosemide | Furosemide | 88 | 23 |
| Prednisone | Prednisone | 84 | 72 |
| Metformin Hcl Er | Metformin Hcl | 82 | 15 |
| Montelukast Sodium | Montelukast Sodium | 80 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | suppressed |
| Bumetanide | Bumetanide | 71 | suppressed |
| Famotidine | Famotidine | 71 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 71 | 13 |
| Sertraline Hcl | Sertraline Hcl | 68 | 15 |
| Glipizide Er | Glipizide | 65 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 63 | 30 |
| Tramadol Hcl | Tramadol Hcl | 62 | 16 |
| Trazodone Hcl | Trazodone Hcl | 62 | suppressed |
| Carvedilol | Carvedilol | 59 | 11 |
| Celecoxib | Celecoxib | 57 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 25 |
| Atenolol | Atenolol | 52 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | suppressed |
| Eliquis | Apixaban | 48 | suppressed |
| Spironolactone | Spironolactone | 48 | suppressed |
| Glimepiride | Glimepiride | 47 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 34 |
| Farxiga | Dapagliflozin Propanediol | 45 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 45 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 44 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 13 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 38 | suppressed |
| Glipizide | Glipizide | 36 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Estradiol | Estradiol | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Alprazolam | Alprazolam | 29 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 23 |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | 13 |
| Baclofen | Baclofen | 25 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Mupirocin | Mupirocin | 24 | 19 |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 18 |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Allopurinol | Allopurinol | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 13 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Sulindac | Sulindac | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Tri-Linyah | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $225.47 · 10 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, JARDIANCE, MOUNJARO, QULIPTA, REXULTI, VRAYLAR, Veozah, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error